Essex Investment Management Co Has Cut Vertex Pharmaceuticals (VRTX) Stake; Aurora Cannabis Inchares (ACB) Shorts Increased By 24.13%

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo

Aurora Cannabis Inchares (NYSE:ACB) had an increase of 24.13% in short interest. ACB’s SI was 90.26 million shares in February as released by FINRA. Its up 24.13% from 72.71 million shares previously. With 17.38 million avg volume, 5 days are for Aurora Cannabis Inchares (NYSE:ACB)’s short sellers to cover ACB’s short positions. The stock increased 1.12% or $0.08 during the last trading session, reaching $7.25. About 19.15M shares traded or 1.08% up from the average. Aurora Cannabis Inc. (NYSE:ACB) has risen 14.37% since February 14, 2018 and is uptrending. It has outperformed by 14.37% the S&P500.

Essex Investment Management Co Llc decreased Vertex Pharmaceuticals Inc (VRTX) stake by 4.92% reported in 2018Q3 SEC filing. Essex Investment Management Co Llc sold 3,188 shares as Vertex Pharmaceuticals Inc (VRTX)’s stock declined 3.07%. The Essex Investment Management Co Llc holds 61,557 shares with $11.86 million value, down from 64,745 last quarter. Vertex Pharmaceuticals Inc now has $47.27 billion valuation. The stock increased 0.67% or $1.24 during the last trading session, reaching $185.25. About 1.24M shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 25.22% since February 14, 2018 and is uptrending. It has outperformed by 25.22% the S&P500. Some Historical VRTX News: 26/04/2018 – Vertex Pharmaceuticals 1Q Rev $640.8M; 03/04/2018 – Vertex Tech Promises Joy of Fast Flight – Metres Above Sea; 26/04/2018 – VERTEX PHARMACEUTICALS INC – COMPANY REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.65 BLN TO $2.80 BLN; 30/05/2018 – FDA slaps a clinical hold on sickle cell IND filed by Vertex and CRISPR Therapeutics $VRTX $CRSP -20%; 06/04/2018 – STAT Plus: New York panel to review Vertex pricing in first test of new law; 01/05/2018 – L3 SIGNS PACT TO SELL VERTEX AEROSPACE BUSINESS TO AMERICAN; 16/04/2018 – Transformational Tax Executive Michael Davis Joins Vertex; 30/05/2018 – CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatmen; 04/05/2018 – L3’s Vertex sold for single-digit adjusted EBITDA multiple; 13/04/2018 – CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018

More notable recent Aurora Cannabis Inc. (NYSE:ACB) news were published by: Seekingalpha.com which released: “Aurora Cannabis: Hitting The Target – Seeking Alpha” on February 12, 2019, also Benzinga.com with their article: “Aurora Cannabis (NYSE:ACB) Revenue More Than Doubles Quarter-Over-Quarter – Benzinga” published on February 11, 2019, Benzinga.com published: “Aurora Cannabis Shares Dive Following $250M Offering News (NYSE:ACB) – Benzinga” on January 17, 2019. More interesting news about Aurora Cannabis Inc. (NYSE:ACB) were released by: Benzinga.com and their article: “What To Expect From Cannabis Stocks This Earnings Season (NYSE:ACB)(NYSE:CGC)(NASDAQ:CRON)(NASDAQ:TLRY) – Benzinga” published on February 07, 2019 as well as Fool.com‘s news article titled: “What Aurora Cannabis’ Q2 Update Could Mean for Canopy Growth – Motley Fool” with publication date: February 14, 2019.

Aurora Cannabis Inc. produces and distributes medical cannabis products. The company has market cap of $7.21 billion. It is vertically integrated and horizontally diversified across various divisions of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. It has a 33.56 P/E ratio. The company's products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Nasdaq.com which released: “Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales – Nasdaq” on February 06, 2019, also Nasdaq.com with their article: “Is a Beat in Store for Vertex (VRTX) This Earnings Season? – Nasdaq” published on January 30, 2019, Nasdaq.com published: “Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates – Nasdaq” on February 05, 2019. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Nasdaq.com and their article: “Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again – Nasdaq” published on January 21, 2019 as well as Nasdaq.com‘s news article titled: “This Is the Best Biotech Stock on the Market – Nasdaq” with publication date: February 10, 2019.

Investors sentiment decreased to 1.06 in 2018 Q3. Its down 0.24, from 1.3 in 2018Q2. It turned negative, as 42 investors sold VRTX shares while 192 reduced holdings. 73 funds opened positions while 176 raised stakes. 231.66 million shares or 2.06% less from 236.55 million shares in 2018Q2 were reported. Northcoast Asset Mngmt Lc has 3,558 shares. British Columbia Investment Management has invested 0.17% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Tocqueville Asset Mngmt Lp stated it has 0.1% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Bb&T Secs Limited Liability Com has invested 0.01% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Tower Limited Liability (Trc) reported 1,715 shares. Adage Capital Grp Incorporated Lc holds 396,012 shares. Fisher Asset Mgmt Lc has 2,198 shares for 0% of their portfolio. 555,080 were accumulated by Timessquare Capital Limited Liability Company. 492,204 are held by Td Asset. First Manhattan Company invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Trexquant Investment Limited Partnership reported 6,646 shares. Jefferies Gp Limited Liability Corp, New York-based fund reported 3,686 shares. Northwestern Mutual Wealth Mgmt invested in 1,941 shares or 0% of the stock. Rmb Mngmt reported 20,496 shares or 0.09% of all its holdings. Connor Clark And Lunn Mngmt Ltd, a British Columbia – Canada-based fund reported 28,550 shares.

Among 7 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Vertex Pharmaceuticals had 10 analyst reports since October 1, 2018 according to SRatingsIntel. The rating was maintained by Raymond James on Thursday, October 25 with “Outperform”. On Wednesday, December 19 the stock rating was maintained by Morgan Stanley with “Overweight”. H.C. Wainwright upgraded the stock to “Buy” rating in Friday, October 26 report. The rating was maintained by Guggenheim on Tuesday, December 18 with “Neutral”. The company was maintained on Friday, January 4 by Citigroup. Raymond James downgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Wednesday, January 2 to “Market Perform” rating. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, November 28. The stock has “Outperform” rating by BMO Capital Markets on Thursday, October 25.

Since August 28, 2018, it had 0 buys, and 34 sales for $26.47 million activity. 2,305 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $430,920 were sold by Kewalramani Reshma. 4,250 shares were sold by Parini Michael, worth $814,215 on Thursday, October 4. Shares for $573,182 were sold by Silva Paul M. Arbuckle Stuart A sold $998,580 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, November 5. $780,598 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by ALTSHULER DAVID. 4,096 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $709,709 were sold by Sachdev Amit. The insider LEIDEN JEFFREY M sold 32,250 shares worth $6.01M.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart